Chicago Equity Partners LLC Invests $406,000 in Alkermes PLC (ALKS)
Chicago Equity Partners LLC purchased a new stake in shares of Alkermes PLC (NASDAQ:ALKS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,000 shares of the company’s stock, valued at approximately $406,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC raised its holdings in Alkermes PLC by 0.4% during the first quarter. FMR LLC now owns 22,882,118 shares of the company’s stock worth $1,338,604,000 after purchasing an additional 86,546 shares in the last quarter. Vanguard Group Inc. grew its position in Alkermes PLC by 4.3% in the first quarter. Vanguard Group Inc. now owns 12,096,635 shares of the company’s stock worth $707,654,000 after buying an additional 497,421 shares during the last quarter. BlackRock Inc. grew its position in Alkermes PLC by 5,927.5% during the 1st quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock worth $602,115,000 after purchasing an additional 10,121,839 shares in the last quarter. Primecap Management Co. CA grew its position in Alkermes PLC by 23.2% during the 1st quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock worth $459,608,000 after purchasing an additional 1,480,273 shares in the last quarter. Finally, Woodford Investment Management Ltd grew its position in Alkermes PLC by 0.3% during the 1st quarter. Woodford Investment Management Ltd now owns 7,470,528 shares of the company’s stock worth $437,026,000 after purchasing an additional 19,400 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.
Shares of Alkermes PLC (ALKS) opened at 52.29 on Thursday. The company has a 50 day moving average of $52.09 and a 200 day moving average of $56.69. The firm’s market cap is $8.03 billion. Alkermes PLC has a 1-year low of $41.93 and a 1-year high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million during the quarter, compared to the consensus estimate of $216.54 million. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. The firm’s revenue was up 12.1% compared to the same quarter last year. On average, equities analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.
In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the sale, the chief accounting officer now owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $54.91, for a total transaction of $82,365.00. Following the sale, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $521,645. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock valued at $941,485 in the last three months. 5.34% of the stock is owned by insiders.
ALKS has been the topic of several research analyst reports. Credit Suisse Group set a $70.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, May 19th. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann cut shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $68.00 to $61.00 in a report on Tuesday, June 13th. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Finally, BidaskClub cut shares of Alkermes PLC from a “hold” rating to a “sell” rating in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $62.89.
Alkermes PLC Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.